These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 20957196)

  • 1. Mass treatment with azithromycin for trachoma control: participation clusters in households.
    Ssemanda EN; Munoz B; Harding-Esch EM; Edwards T; Mkocha H; Bailey RL; Sillah A; Stare D; Mabey DC; West SK;
    PLoS Negl Trop Dis; 2010 Oct; 4(10):. PubMed ID: 20957196
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Azithromycin mass treatment for trachoma control: risk factors for non-participation of children in two treatment rounds.
    Ssemanda EN; Levens J; Mkocha H; Munoz B; West SK
    PLoS Negl Trop Dis; 2012; 6(3):e1576. PubMed ID: 22448296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mass treatment with azithromycin for trachoma: when is one round enough? Results from the PRET Trial in the Gambia.
    Harding-Esch EM; Sillah A; Edwards T; Burr SE; Hart JD; Joof H; Laye M; Makalo P; Manjang A; Molina S; Sarr-Sissoho I; Quinn TC; Lietman T; Holland MJ; Mabey D; West SK; Bailey R;
    PLoS Negl Trop Dis; 2013; 7(6):e2115. PubMed ID: 23785525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design and baseline data of a randomized trial to evaluate coverage and frequency of mass treatment with azithromycin: the Partnership for Rapid Elimination of Trachoma (PRET) in Tanzania and The Gambia.
    Stare D; Harding-Esch E; Munoz B; Bailey R; Mabey D; Holland M; Gaydos C; West S
    Ophthalmic Epidemiol; 2011 Feb; 18(1):20-9. PubMed ID: 21275593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting antibiotics to households for trachoma control.
    Blake IM; Burton MJ; Solomon AW; West SK; Basáñez MG; Gambhir M; Bailey RL; Mabey DC; Grassly NC
    PLoS Negl Trop Dis; 2010 Nov; 4(11):e862. PubMed ID: 21072225
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-participation during azithromycin mass treatment for trachoma in The Gambia: heterogeneity and risk factors.
    Edwards T; Allen E; Harding-Esch EM; Hart J; Burr SE; Holland MJ; Sillah A; West SK; Mabey D; Bailey R
    PLoS Negl Trop Dis; 2014 Aug; 8(8):e3098. PubMed ID: 25165994
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Can we stop mass drug administration prior to 3 annual rounds in communities with low prevalence of trachoma?: PRET Ziada trial results.
    Yohannan J; Munoz B; Mkocha H; Gaydos CA; Bailey R; Lietman TA; Quinn T; West SK
    JAMA Ophthalmol; 2013 Apr; 131(4):431-6. PubMed ID: 23392481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk factors for ocular infection with Chlamydia trachomatis in children 6 months following mass treatment in Tanzania.
    Cajas-Monson LC; Mkocha H; Muñoz B; Quinn TC; Gaydos CA; West SK
    PLoS Negl Trop Dis; 2011 Mar; 5(3):e978. PubMed ID: 21423645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trachoma and ocular Chlamydia trachomatis were not eliminated three years after two rounds of mass treatment in a trachoma hyperendemic village.
    West SK; Munoz B; Mkocha H; Gaydos C; Quinn T
    Invest Ophthalmol Vis Sci; 2007 Apr; 48(4):1492-7. PubMed ID: 17389476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Number of years of annual mass treatment with azithromycin needed to control trachoma in hyper-endemic communities in Tanzania.
    West SK; Munoz B; Mkocha H; Gaydos CA; Quinn TC
    J Infect Dis; 2011 Jul; 204(2):268-73. PubMed ID: 21673038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of a single round of mass drug administration with azithromycin on active trachoma and ocular Chlamydia trachomatis prevalence and circulating strains in The Gambia and Senegal.
    Harding-Esch EM; Holland MJ; Schémann JF; Sillah A; Sarr B; Christerson L; Pickering H; Molina-Gonzalez S; Sarr I; Andreasen AA; Jeffries D; Grundy C; Mabey DCW; Herrmann B; Bailey RL
    Parasit Vectors; 2019 Oct; 12(1):497. PubMed ID: 31640755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of Active and Latent Yaws in the Solomon Islands 18 Months after Azithromycin Mass Drug Administration for Trachoma.
    Marks M; Sokana O; Nachamkin E; Puiahi E; Kilua G; Pillay A; Bottomley C; Solomon AW; Mabey DC
    PLoS Negl Trop Dis; 2016 Aug; 10(8):e0004927. PubMed ID: 27551787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Surveillance and Azithromycin Treatment for Newcomers and Travelers Evaluation (ASANTE) Trial: Design and Baseline Characteristics.
    Ervin AM; Mkocha H; Munoz B; Dreger K; Dize L; Gaydos C; Quinn TC; West SK
    Ophthalmic Epidemiol; 2016 Dec; 23(6):347-353. PubMed ID: 27820670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk factors for ocular chlamydia after three mass azithromycin distributions.
    Ayele B; Gebre T; Moncada J; House JI; Stoller NE; Zhou Z; Porco TC; Gaynor BD; Emerson PM; Schachter J; Keenan JD
    PLoS Negl Trop Dis; 2011 Dec; 5(12):e1441. PubMed ID: 22180804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Infection with Chlamydia trachomatis after mass treatment of a trachoma hyperendemic community in Tanzania: a longitudinal study.
    West SK; Munoz B; Mkocha H; Holland MJ; Aguirre A; Solomon AW; Foster A; Bailey RL; Mabey DC
    Lancet; 2005 Oct; 366(9493):1296-300. PubMed ID: 16214600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population-based coverage survey results following the mass drug administration of azithromycin for the treatment of trachoma in Amhara, Ethiopia.
    Astale T; Sata E; Zerihun M; Nute AW; Stewart AEP; Gessese D; Ayenew G; Melak B; Chanyalew M; Tadesse Z; Callahan EK; Nash SD
    PLoS Negl Trop Dis; 2018 Feb; 12(2):e0006270. PubMed ID: 29451881
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Do infants increase the risk of re-emergent infection in households after mass drug administration for trachoma?
    West SK; Stare D; Mkocha H; Munoz B; Gaydos C; Quinn TC
    Invest Ophthalmol Vis Sci; 2011 Jul; 52(8):6040-2. PubMed ID: 21680866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population coverage and factors associated with participation following a mass drug administration of azithromycin for trachoma elimination in Amhara, Ethiopia.
    Ebert CD; Astale T; Sata E; Zerihun M; Nute AW; Stewart AEP; Gessese D; Ayenew G; Ayele Z; Melak B; Chanyalew M; Gashaw B; Tadesse Z; Callahan EK; Jenness SM; Nash SD
    Trop Med Int Health; 2019 Apr; 24(4):493-501. PubMed ID: 30674087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Coverage of azithromycin mass treatment for trachoma elimination in Northwestern Ethiopia: a community based cross-sectional study.
    Tilahun Z; Fenta TG
    BMC Ophthalmol; 2018 Aug; 18(1):193. PubMed ID: 30081851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Re-emergence of Chlamydia trachomatis infection after mass antibiotic treatment of a trachoma-endemic Gambian community: a longitudinal study.
    Burton MJ; Holland MJ; Makalo P; Aryee EA; Alexander ND; Sillah A; Faal H; West SK; Foster A; Johnson GJ; Mabey DC; Bailey RL
    Lancet; 2005 Apr 9-15; 365(9467):1321-8. PubMed ID: 15823382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.